ArticleCureus2025
Immunoadsorption-Based Desensitization With Column Reuse in ABO-Incompatible Living Donor Renal Transplantation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coagulation Assessment and Fibrinogen Thresholds in Therapeutic Plasma Exchange-A Narrative Review.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionABO-incompatible kidney transplantation (ABOi-KT) has become a viable solution to expand access to living donor transplantation, particularly in countries where deceased donor programs are limited. Immunoadsorption (IA) enables selective antibody removal and is widely preferred, but the high cost of single-use IA columns restricts its routine use in low-resource settings. To address this challenge, some Indian centers have adopted structured column reuse under controlled protocols. This study was undertaken to evaluate the clinical safety, immunological efficacy, and practical feasibility of an IA-based desensitization protocol incorporating planned column reuse.
aimTo evaluate the efficacy and safety of immunoadsorption-based desensitization using structured column reuse in ABO-incompatible transplantation. MATERIALS AND
methodsThis was a retrospective study of 13 adult patients who underwent living donor ABO-incompatible kidney transplantation between June 2023 and May 2025. Desensitization involved IA with selective column reuse under validated sterile conditions. All patients received standardized immunosuppression, and isoagglutinin titers were serially monitored. Outcomes included titer reduction, graft function, antibody rebound, rejection episodes, and procedure-related complications. Statistical analysis was performed using standard methods, with p < 0.05 considered significant.
resultsThirty-five IA sessions were conducted; 60% involved column reuse. Final IgG and IgM titers ≤1:8 were achieved in all patients prior to transplantation. Immediate graft function was seen in 12 patients. Mean serum creatinine at discharge was 1.07 mg/dL. No cases of antibody-mediated rejection, post-transplant isoagglutinin rebound, or reuse-related adverse events were observed. No patients required blood product transfusion or additional apheresis post-transplant. At three months, all patients had functioning grafts, with 100% patient and graft survival. The protocol demonstrated safety, efficacy, and feasibility within a cost-constrained setting.
conclusionImmunoadsorption with structured column reuse is an effective, safe, and practical desensitization strategy in ABO-incompatible transplantation, offering a viable approach in resource-limited healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.